Clinical trial
A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of JY232 Injection in Patients With Relapsed/Refractory Multiple Myeloma
NCT07336823 is registered in ClinicalTrials.gov with Shenzhen Genocury Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of JY232 Injection in Patients With Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Shenzhen Genocury Biotech Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- January 20, 2026
- Completion date
- December 31, 2028
- Enrollment
- 9 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.